2017 revenues: $9,048,000,000
2017 R&D spend: $997,000,000
Fiscal year ending: December 31, 2017
Michael Mahoney, president and CEO; Kevin Ballinger, SVP and president, interventional cardiology; Daniel Brennan, EVP & CFO; Desiree Ralls-Morrison, SVP, general counsel and corporate secretary; Wendy Carruthers, SVP, HR; Art Butcher, SVP and president, endoscopy; Joseph Fitzgerald, EVP and president, rhythm management; Edward Mackey, EVP, operations; Jeff Mirviss, SVP and president, peripheral interventions; Maulik Nanavaty, SVP and president, neuromodulation; Ian Meredith, EVP and global chief medical officer; David Pierce, EVP and president, MedSurg; Brad Sorenson, SVP, manufacturing and supply Chain; Eric Thépaut, SVP and president, Europe; Warren Wang, SVP and president, Asia Pacific
Turnaround complete, Boston Scientific focused its eye to streamlining its operations via a clutch of acquisitions aimed at rounding out its portfolio: stent developer Veniti (August, $160 million); Claret Medical and its Sentinel anti-stroke TAVR device (August, $270 million); Cryterion Medical and its single-shot cryoablation device for atrial fibrillation (July, $202 million); 400m NxThera and its Rezūm benign prostatic hyperplasia device (April, $275 million); women’s health-focused NVision Medical (April, undisclosed); a stake in thermal body mapping device maker Securus Medical (April, $40 million); endoscope maker EMcision (March, undisclosed); a position in Millepede with an option to buy (January, $90 million); and Apama Medical and its radiofrequency balloon catheter (October 2017, $300 million). The M&A news didn’t stop there: a false rumor that posited the company as a buyout target for Stryker roiled the markets in June.
Boston Scientific was also nominated for two Prix Galien awards for its SpyGlass DS direct visualization system used for cholangiopancreatoscopy and Watchman left atrial appendage closure device.
And although CEO Mike Mahoney punted Boston’s entry into the transcatheter aortic valve market, Lotus, into next year, the news wasn’t all bad: Mahoney was named Employee’s Choice number two in Glassdoor.com’s survey of the top CEOs of 2018.